Literature DB >> 24240933

Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile.

Seth S Martin1, Michael J Blaha, Mohamed B Elshazly, Peter P Toth, Peter O Kwiterovich, Roger S Blumenthal, Steven R Jones.   

Abstract

IMPORTANCE: In clinical and research settings worldwide, low-density lipoprotein cholesterol (LDL-C) is typically estimated using the Friedewald equation. This equation assumes a fixed factor of 5 for the ratio of triglycerides to very low-density lipoprotein cholesterol (TG:VLDL-C); however, the actual TG:VLDL-C ratio varies significantly across the range of triglyceride and cholesterol levels.
OBJECTIVE: To derive and validate a more accurate method for LDL-C estimation from the standard lipid profile using an adjustable factor for the TG:VLDL-C ratio. DESIGN, SETTING, AND PARTICIPANTS: We used a convenience sample of consecutive clinical lipid profiles obtained from 2009 through 2011 from 1,350,908 children, adolescents, and adults in the United States. Cholesterol concentrations were directly measured after vertical spin density-gradient ultracentrifugation, and triglycerides were directly measured. Lipid distributions closely matched the population-based National Health and Nutrition Examination Survey (NHANES). Samples were randomly assigned to derivation (n = 900,605) and validation (n = 450,303) data sets. MAIN OUTCOMES AND MEASURES: Individual patient-level concordance in clinical practice guideline LDL-C risk classification using estimated vs directly measured LDL-C (LDL-CD).
RESULTS: In the derivation data set, the median TG:VLDL-C was 5.2 (IQR, 4.5-6.0). The triglyceride and non-high-density lipoprotein cholesterol (HDL-C) levels explained 65% of the variance in the TG:VLDL-C ratio. Based on strata of triglyceride and non-HDL-C values, a 180-cell table of median TG:VLDL-C values was derived and applied in the validation data set to estimate the novel LDL-C (LDL-CN). For patients with triglycerides lower than 400 mg/dL, overall concordance in guideline risk classification with LDL-CD was 91.7% (95% CI, 91.6%-91.8%) for LDL-CN vs 85.4% (95% CI, 85.3%-85.5%) for Friedewald LDL-C (LDL-CF) (P < .001). The greatest improvement in concordance occurred in classifying LDL-C lower than 70 mg/dL, especially in patients with high triglyceride levels. In patients with an estimated LDL-C lower than 70 mg/dL, LDL-CD was also lower than 70 mg/dL in 94.3% (95% CI, 93.9%-94.7%) for LDL-CN vs 79.9% (95% CI, 79.3%-80.4%) for LDL-CF in samples with triglyceride levels of 100 to 149 mg/dL; 92.4% (95% CI, 91.7%-93.1%) for LDL-CN vs 61.3% (95% CI, 60.3%-62.3%) for LDL-CF in samples with triglyceride levels of 150 to 199 mg/dL; and 84.0% (95% CI, 82.9%-85.1%) for LDL-CN vs 40.3% (95% CI, 39.4%-41.3%) for LDL-CF in samples with triglyceride levels of 200 to 399 mg/dL (P < .001 for each comparison). CONCLUSIONS AND RELEVANCE: A novel method to estimate LDL-C using an adjustable factor for the TG:VLDL-C ratio provided more accurate guideline risk classification than the Friedewald equation. These findings require external validation, as well as assessment of their clinical importance. The implementation of these findings into clinical practice would be straightforward and at virtually no cost. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01698489.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24240933      PMCID: PMC4226221          DOI: 10.1001/jama.2013.280532

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  36 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

3.  Very large database of lipids: rationale and design.

Authors:  Seth S Martin; Michael J Blaha; Peter P Toth; Parag H Joshi; John W McEvoy; Haitham M Ahmed; Mohamed B Elshazly; Kristopher J Swiger; Erin D Michos; Peter O Kwiterovich; Krishnaji R Kulkarni; Joseph Chimera; Christopher P Cannon; Roger S Blumenthal; Steven R Jones
Journal:  Clin Cardiol       Date:  2013-10-01       Impact factor: 2.882

4.  Should we fast before we measure our lipids?

Authors:  J Michael Gaziano
Journal:  Arch Intern Med       Date:  2012-12-10

5.  Ratio of remnant-like particle-cholesterol to serum total triglycerides is an effective alternative to ultracentrifugal and electrophoretic methods in the diagnosis of familial type III hyperlipoproteinemia.

Authors:  T Wang; K Nakajima; E T Leary; G R Warnick; J S Cohn; P N Hopkins; L L Wu; D D Cilla; J Zhong; R J Havel
Journal:  Clin Chem       Date:  1999-11       Impact factor: 8.327

Review 6.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

Authors:  D S Fredrickson; R I Levy; R S Lees
Journal:  N Engl J Med       Date:  1967-01-12       Impact factor: 91.245

7.  Fasting time and lipid levels in a community-based population: a cross-sectional study.

Authors:  Davinder Sidhu; Christopher Naugler
Journal:  Arch Intern Med       Date:  2012-12-10

Review 8.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

9.  Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications.

Authors:  Seth S Martin; Michael J Blaha; Mohamed B Elshazly; Eliot A Brinton; Peter P Toth; John W McEvoy; Parag H Joshi; Krishnaji R Kulkarni; Patrick D Mize; Peter O Kwiterovich; Andrew P Defilippis; Roger S Blumenthal; Steven R Jones
Journal:  J Am Coll Cardiol       Date:  2013-03-21       Impact factor: 24.094

10.  A new accurate, simple formula for LDL-cholesterol estimation based on directly measured blood lipids from a large cohort.

Authors:  Caio Mauricio Mendes de Cordova; Mauricio Mendes de Cordova
Journal:  Ann Clin Biochem       Date:  2012-10-29       Impact factor: 2.057

View more
  147 in total

1.  Compromised endothelial function in transgender men taking testosterone.

Authors:  Barbara I Gulanski; Clare A Flannery; Patricia R Peter; Cheryl A Leone; Nina S Stachenfeld
Journal:  Clin Endocrinol (Oxf)       Date:  2019-12-13       Impact factor: 3.478

2.  Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm.

Authors:  Samia Mora; C Lan Chang; M Vinayaga Moorthy; Peter S Sever
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

3.  Time-restricted feeding plus resistance training in active females: a randomized trial.

Authors:  Grant M Tinsley; M Lane Moore; Austin J Graybeal; Antonio Paoli; Youngdeok Kim; Joaquin U Gonzales; John R Harry; Trisha A VanDusseldorp; Devin N Kennedy; Megan R Cruz
Journal:  Am J Clin Nutr       Date:  2019-09-01       Impact factor: 7.045

4.  PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.

Authors:  Maciej Banach; Piotr Jankowski; Jacek Jóźwiak; Barbara Cybulska; Adam Windak; Tomasz Guzik; Artur Mamcarz; Marlena Broncel; Tomasz Tomasik; Jacek Rysz; Agnieszka Jankowska-Zduńczyk; Piotr Hoffman; Agnieszka Mastalerz-Migas
Journal:  Arch Med Sci       Date:  2016-12-19       Impact factor: 3.318

5.  Reply to the Comment Entitled "Martin Method for Estimation of Low-Density Lipoprotein Cholesterol".

Authors:  Soie Chung
Journal:  Med Princ Pract       Date:  2018-09-10       Impact factor: 1.927

6.  Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study.

Authors:  Renato Quispe; Mohamed B Elshazly; Di Zhao; Peter P Toth; Rishi Puri; Salim S Virani; Roger S Blumenthal; Seth S Martin; Steven R Jones; Erin D Michos
Journal:  Eur J Prev Cardiol       Date:  2019-07-10       Impact factor: 7.804

7.  Effect of atorvastatin on dyslipidemia and carotid intima-media thickness in children with refractory nephrotic syndrome: a randomized controlled trial.

Authors:  Pankaj Hari; Priyanka Khandelwal; Amit Satpathy; Smriti Hari; Ranjeet Thergaonkar; R Lakshmy; Aditi Sinha; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2018-08-08       Impact factor: 3.714

8.  Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry.

Authors:  Avinainder Singh; Bradley L Collins; Ankur Gupta; Amber Fatima; Arman Qamar; David Biery; Julio Baez; Mary Cawley; Josh Klein; Jon Hainer; Jorge Plutzky; Christopher P Cannon; Khurram Nasir; Marcelo F Di Carli; Deepak L Bhatt; Ron Blankstein
Journal:  J Am Coll Cardiol       Date:  2017-11-12       Impact factor: 24.094

9.  The Future of Low-Density Lipoprotein Cholesterol in an Era of Nonfasting Lipid Testing and Potent Low-Density Lipoprotein Lowering.

Authors:  Zareen Farukhi; Samia Mora
Journal:  Circulation       Date:  2018-01-02       Impact factor: 29.690

10.  Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort.

Authors:  Eric J Brandt; Arya Mani; Erica S Spatz; Nihar R Desai; Khurram Nasir
Journal:  J Clin Lipidol       Date:  2020-07-03       Impact factor: 4.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.